Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.59
(
1.88%
)
Bitcoin
70,697.87
(
-0.76%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 52937

Thursday, 09/27/2007 3:52:42 PM

Thursday, September 27, 2007 3:52:42 PM

Post# of 257257
>Other C1-INHs are in development for HAE, but we believe LEVP will likely receive 7 years of Orphan exclusivity in the U.S. for Cinryze.<

Pharming obviously disagrees. One possibility is that the FDA grants separate orphan exclusivity for prophylactic HAE and acute HAE, although this seems unjustified by the orphan regs themselves.

Comments?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now